Clinical efficacy and safety of linagliptin in patients with diabetes type 2
Treatment of diabetes mellitus type 2 (T2DM) is a serious challenge which forces to search for new approaches in order to improve the results of pharmacotherapy. Recent advances in diabetology pertain to incretin-directed therapies. Along with traditional defects (insulin resistance, β-cell dysfunct...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2016-12-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/55 |
| _version_ | 1797842142355259392 |
|---|---|
| author | E. V. Biryukova A. M. Mkrtumyan |
| author_facet | E. V. Biryukova A. M. Mkrtumyan |
| author_sort | E. V. Biryukova |
| collection | DOAJ |
| description | Treatment of diabetes mellitus type 2 (T2DM) is a serious challenge which forces to search for new approaches in order to improve the results of pharmacotherapy. Recent advances in diabetology pertain to incretin-directed therapies. Along with traditional defects (insulin resistance, β-cell dysfunction), a significant contribution to the development and progression of the disease is made by a reduction of "incretin effect" (Fig. 1). The concept of reduced "incretin effect" served as the basis for the development and introduction into clinical practice of the innovative medications the action of which is based on the "incretin effect" - glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP). [12, 17]. |
| first_indexed | 2024-04-09T16:43:00Z |
| format | Article |
| id | doaj.art-fd4f73df13d8475b9eecd1fa66a78fdd |
| institution | Directory Open Access Journal |
| issn | 2079-701X 2658-5790 |
| language | Russian |
| last_indexed | 2024-04-09T16:43:00Z |
| publishDate | 2016-12-01 |
| publisher | Remedium Group LLC |
| record_format | Article |
| series | Медицинский совет |
| spelling | doaj.art-fd4f73df13d8475b9eecd1fa66a78fdd2023-04-23T06:56:38ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902016-12-0103242910.21518/2079-701X-2016-3-24-2955Clinical efficacy and safety of linagliptin in patients with diabetes type 2E. V. Biryukova0A. M. Mkrtumyan1First Moscow State University of Medicine and Dentistry named after A.I. EvdokimovFirst Moscow State University of Medicine and Dentistry named after A.I. EvdokimovTreatment of diabetes mellitus type 2 (T2DM) is a serious challenge which forces to search for new approaches in order to improve the results of pharmacotherapy. Recent advances in diabetology pertain to incretin-directed therapies. Along with traditional defects (insulin resistance, β-cell dysfunction), a significant contribution to the development and progression of the disease is made by a reduction of "incretin effect" (Fig. 1). The concept of reduced "incretin effect" served as the basis for the development and introduction into clinical practice of the innovative medications the action of which is based on the "incretin effect" - glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP). [12, 17].https://www.med-sovet.pro/jour/article/view/55сахарный диабет 2-го типаинкретин-направленная терапиялинаглиптинtype 2 diabetesincretin-directed therapylinagliptin |
| spellingShingle | E. V. Biryukova A. M. Mkrtumyan Clinical efficacy and safety of linagliptin in patients with diabetes type 2 Медицинский совет сахарный диабет 2-го типа инкретин-направленная терапия линаглиптин type 2 diabetes incretin-directed therapy linagliptin |
| title | Clinical efficacy and safety of linagliptin in patients with diabetes type 2 |
| title_full | Clinical efficacy and safety of linagliptin in patients with diabetes type 2 |
| title_fullStr | Clinical efficacy and safety of linagliptin in patients with diabetes type 2 |
| title_full_unstemmed | Clinical efficacy and safety of linagliptin in patients with diabetes type 2 |
| title_short | Clinical efficacy and safety of linagliptin in patients with diabetes type 2 |
| title_sort | clinical efficacy and safety of linagliptin in patients with diabetes type 2 |
| topic | сахарный диабет 2-го типа инкретин-направленная терапия линаглиптин type 2 diabetes incretin-directed therapy linagliptin |
| url | https://www.med-sovet.pro/jour/article/view/55 |
| work_keys_str_mv | AT evbiryukova clinicalefficacyandsafetyoflinagliptininpatientswithdiabetestype2 AT ammkrtumyan clinicalefficacyandsafetyoflinagliptininpatientswithdiabetestype2 |